The results of animal challenge experiments show that the COVID-19 immunotherapy drug AD17002-SC can significantly reduce the lung inflammation caused by moderate to severe virus infections.
The results of animal challenge experiments show that the COVID-19 immunotherapy drug AD17002-SC can significantly reduce the lung inflammation caused by moderate to severe virus infections.
2020-12-23
